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ABSTRACT
Alendronate is one of the most commonly prescribed drugs for the treatment of osteoporosis
and other diseases characterized by increased bone resorption. Poor compliance increases the fracture risks, and ultimately treatment failure. This study aims to evaluate Palestinian pharmacist’s
knowledge of the proper administration instructions, interactions and side effects of Alendronate as
this significantly affect the medical effectiveness and the development of adverse effects. Self- administered questionnaires were completed by 230 pharmacists working in community pharmacies
in the northern area of the West Bank. Data were collected using a validated questionnaire consisting of 4 sections and analyzed by descriptive statistics. A scoring scheme was developed to estimate the knowledge scores of participants for the various parameters. The obtained knowledge
scores were correlated with the socio-demographics characteristics of the pharmacist's. The median
knowledge score of the pharmacists regarding the proper use of Alendronate was moderate i.e., 6
out of a possible maximum score of 9. The knowledge score of Alendronate interactions with food
and other medications was 10.5 out of a possible maximum of 14 which is considered as a moderate score, whereas, that for side effects was 4 (0-8). Factors affecting the knowledge towards Alendronate dosing instructions, side effects, and interactions were gender, employment status, years of
experience and work place. In conclusion, Palestinian pharmacists have intermediate knowledge
about the proper use, drug-food interactions and side effects of Alendronate. Knowledge gaps were
identified by this study. Therefore, improving pharmacist's knowledge is of great importance to
achieve better efficacy and safety from the treatment.
Keywords: Osteoporosis, Alendronate, Dosing instructions, Knowledge.
INTRODUCTION
Osteoporosis is a degenerative bone disease characterized by low bone mass and an
increased susceptibility to fractures that is
common in postmenopausal women.
Bisphosphonates are commonly prescribed
for the treatment of osteoporosis. They exert
their effects by increasing bone mineral density and inhibiting the osteoclast-mediated
bone resorbtion, thus, reducing the incidence
of major osteoporotic fractures (1, 2). The
adherence to oral bisphosphonates therapy
among patients was shown to be inadequate
(3, 4). Such poor adherence was associated
with a lower rate of bone turnover and greater risk of fractures (5, 6, 7). About 75% of
postmenopausal women who took oral
bisphosphonates were non adherent to the
treatment within one year and half of patients

stop their therapy by this time (8). Similar
findings were reported by Weycker et.al,
2006. The overall compliance rate of patients
was approximately 40% one year after the
initial dose (9). The compliance and persistence in patients using bisphosphonates
weekly was better than those using them daily, but in both cases persistence rate was
suboptimal (10,11). The most common barriers for optimal adherence included: the experienced adverse effects (GI intolerance) and
the complex dosing requirements (9, 12, 13,
14).
The oral bioavailability of Alendronate
is low (0.75% in the fasting state). Coadministration of the drug with food, black
coffee,orange juice, mineral water and dairy
products was shown to further decrease the
oral absorption of Alendronate. Moreover,
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medications containing calcium salts, iron,
magnesium salts, antacids and multivitamins
can further reduce the absorption of Alendronate (15, 16). The concomitant intake of aspirin and non-steroidal anti-inflammatory
agents (NSAIDs) may increase the incidence
of upper gastrointestinal side effects of Alendronate and the risk of nephrotoxicity. Food
and drug interactions with Alendronate may
lead to treatment failure, as the oral bioavailability may decline to negligible levels. For
this reason, dosing instructions require that
bisphosphonates should be administered in
the early morning at least 30 minutes before
breakfast or other medications with 6 to 8
ounces of plain water and to remain in upright either sitting or standing for at least 30
minutes after dose administration (17).
Poor understanding of dosing instructions by patients could increase the risk of
adverse effects and reduce the therapeutic
effectiveness of the drug or may result in
poor adherence. Adherence to the dosing instructions will reduce the risk of the side effects.
The pharmacist is responsible for educating the patient about the proper dosing information to minimize adverse effects severity and incorrect use of the drug. Pharmacists
should provide patient counseling about
Alendronate adverse effects, dose instructions, drug-drug interactions and drug food
interactions. Therefore, improving the outcomes of the therapeutic process will depend
to a great extent on the knowledge of pharmacists about the proper dosing information.
A wide variability in pharmacists' knowledge
toward the correct administration instructions
of Alendronate can lead to poor compliance.
Thus identifying the knowledge deficit is
important (18, 19).
Pharmacist's knowledge of Alendronate
doing information has not been widely studied. A previous study was conducted to assess the knowledge of pharmacists toward the
proper dosing instructions of three bisphosphonates (Alendronate, Risedronate and
Etidronate) in British Columbia, Canada. A
wide range of knowledge basis regarding the
proper use of bisphosphonates was shown.
The study, which involved 163 community
pharmacy practitioners, showed higher

knowledge scores for the questions related to
Alendronate than Etidronate and Residronate.
The pharmacists demonstrated less awareness
of some general dosing principles such as the
need to remain in upright position after drug
intake, drug spacing from other mediations,
food and drinks. Pharmacists who were employed in higher volume pharmacies and
those who had higher number of years in
practice had higher knowledge scores (20).
Palestinian pharmacists' knowledge toward the dosing instructions and interactions
of Alendronate has not been studied before.
The main objectives of this study were to
assess community pharmacists’ knowledge of
the proper administration instructions of
Alendronate and the potential Alendronate drug and Alendronate -food interactions as
this significantly correlates with the medical
effectiveness and development of adverse
effects. Part of the aim of this study is to
highlight the therapeutic role of community
pharmacists on improving medication adherence and maximizing the therapeutic efficacy
of Alendronate therapy.
MATERIALS AND METHODS
Study design
This is a cross sectional study using a
self-administered questionnaire that was conducted in the time period between July 2015
and December 2015. The population of the
study was 230 pharmacists working in community pharmacies in the Northern area of
the West Bank, which consist of 4 governorates: Nablus, Qalqiliah, Jenin and
Tulkarem.
The tools of the study
The questionnaire used in the tool consisted of four parts: the first section consisted
of general demographic data of the pharmacist, which included: gender, age, workplace,
education level and years of experience. The
second section was measuring pharmacist's
knowledge of the proper use instructions, and
contained 9 questions. These were multiplechoice questions and were designed to test
pharmacist's information about the proper
dosing instruction of Alendronate. A
knowledge score was defined as the number
of correct answers to the 9 questions that
evaluated the participants’ knowledge of
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Alendronate use. The respondent had a good
knowledge when the total score ranged from
7 to 9points; intermediate knowledge if the
total score ranged from 4 to 6 points and the
respondent had a poor knowledge if the total
score ranged from 0 to 3 points. The third
section was designed to measure the
knowledge of pharmacists about Alendronate
food and drugs interactions; it contained 15
questions. This section offered the following
answers: yes, no, I don’t know. The respondent had a good level of knowledge if the total
knowledge score ranged from 11 to 15
points; intermediate knowledge if the total
score ranged from 6 to 10 points and the respondents had a poor knowledge if the total
score ranged from 0 to 5 points. The fourth
section was to assess pharmacist's knowledge
about the common adverse effects of Alendronate; it contained 8 questions.
This section consisted of the following
answers: yes, no, I don’t know. The respondent had a good level of knowledge when the
total knowledge score ranged from 6 to 8
points, whereas, the respondent had intermediate knowledge if the total score ranged
from 3 to 5 points and poor knowledge if the
total score ranged from 0 to 2 points.
Ethical Considerations
The study protocol was approved by the
Institutional Review Board (IRB) committee
at An-Najah National University, Palestine.
The authors obtained verbal consent from the
community pharmacists who participated in
the study.
Statistical analysis
Data were analyzed using Statistical
package for social sciences program version
(6) (SPSS). Continuous variables were expressed as mean ±SD, while categorical variable were expressed frequency. Mann-witney
test used for gender, work place, work type
and employment status, whereas, kruksalwallis H test used for work locality, educational level, and expert years.
RESULTS
Socio-demographic of the pharmacists

surveys were answered by male (50.4%). The
ages of the pharmacists were divided into
five categories, with the category (20-29
year) being the highest in frequency 43.8%
(n=101). About 61.7% (n=142) pharmacists
were primarily from pharmacies located in
urban areas, whereas, 34.3% (n=79) were
from rural area. The majority of the pharmacists 86.1% (n=198) had a bachelor of pharmacy level of education. About 61.3%
(n=141) were employees in the pharmacies
and not pharmacy owners.
Knowledge of the pharmacist's about the
proper alendronate administration instructions
In this section, the pharmacists were
asked about the proper administration instructions for Alendronate as a medicine for
the treatment of osteoporosis (Table 1). All
of participants were able to recognize Alendronate and 88.3% (n=203) of them believed
that they have sufficient knowledge about
this drug. The sources of this knowledge
were reported to be from the university studies (40%, n=92), the practice experience
(37%, n=85), drug leaflets (16.1%, n=37) and
media (4.3%, n=10), whereas 2.6% (n=6)
could not remember their information source.
The weekly dose of Alendronate (70mg)
was recognized by the pharmacists to be the
most commonly dispensed dose in their
pharmacies (87%, n=200). Regarding the
daily dose (10 mg) inquires, the pharmacists
were asked about their recommendations if
the patients missed their daily dose: 31.3%
(n=72) of the pharmacists recommended taking the missed dose as soon as they remembered, 48.7% (n=112) of the pharmacists advised skipping the missed dose, while 20%
(n=46) of pharmacists recommended taking
the missed dose and the following dose together.
On the other hand, if the patients missed
their weekly dose, 78.3% (n=180) of the
pharmacists answered correctly: to take the
tablet the next day of the same week and return to taking the dose once a week as originally scheduled.

The total number of surveys distributed
was 264, of which 230 were returned back
(response rate 87.12%). Nearly half of the
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Table (1): The knowledge about the proper administration instructions of Alendronate.
Variable
Frequency for correct answer
Forgotten daily dose
Take it as soon as you remember
72 (31.3%)
Forgotten weekly dose
Take the tablet on the morning once remembered and return to 180 (78.3%)
taking one tablet once a week as originally scheduled.
It's important to take the dose in the same time weekly or daily
Yes
217 (94.3%)
What is the usual time for taking it
Morning
170 (73.9%)
Timing of Alendronate intake regarding to meal
Thirty mint before meal intake
137 (59.6%)
Amount of water normally taken with it
Large cup
196 (85.2%)
It's important to take a special position while dose intake
Yes
206 (89.6%)
Pharmacist advice patient for up-right position while dose intake
Yes
172 (74.8%)
What to do if the patient take an over dose
Taking a glass of milk
167 (72.6%)
The time that patients can continue taking Alendronate
It does not matter; It can continue as it wants
66 (28.7%)
Patients counseling
Yes
219 (95.2%)
Advising patient for leaflet reading
Yes
164 (71.3%)
No
66 (28.7%)
It's important for patient to notice their dentist about Alendronate
Yes
97 (42.2%)
No
133 (57.8%)
Timing between alendronate and other medication
Take Alendronate 30 minutes before other drugs
163(70.9%)
one hour before the meal, 9.6% (n=22) recWhile 8.3% (n=19) of pharmacists recommend taking the drug immediately before
ommended taking two tablets in the next
the meal. While small percentage of pharmaweek at the same time, and 13.5% (n=31)
cists recommended to take the drug one hour
pharmacists advised to ignore the missed
after the meal, or didn't know the answer.
dose and take the same usual dose in the next
Regarding the amount of water to be taken
week. The majority of the pharmacists
with the drug, the majority of the pharmacists
(94.3%, n=217) emphasized the importance
(85.2%, n=196) advised to take a large cup of
of taking Alendronate dose at the same time
water, whereas, only 12.6% (n=29) with
either daily or weekly with the favoring time
small cup of water, While 2.2% (n=5) of
for intake of Alendronate the morning73.9%
pharmacists didn't know the answer. The ma(n=170). When the pharmacists were asked
jority of pharmacists recognized the imabout the timing of the drug with regards to
portance of the body position with Alendrofood. The results indicated that 59.6%
nate dose intake (89.6 %, n=206) and was
(n=137) of the pharmacists recommended
able to identify the up-right position as the
taking the drug 30 minutes before the meal,
most appropriate position (74.8%, n=172).
20% (n=46) recommended to take the drug
About 72.6% (n=167) of the pharmacists
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recommended drinking a glass of milk in
case of overdose of Alendronate. Regarding
the duration of Alendronate therapy, 41.7%
(n=96) of the pharmacists thought that the
duration must not exceed 1 to 2 year, 29.6%
(n=68) the duration must not exceed 3 to 5
year. While 28.7% (n=66) of the pharmacists
answered the patients can continue their therapy as long as they can.
The majority of the pharmacists (95.2%)
reported providing adequate counseling about
the proper way for administration of Alendronate while dispensing the alendronate
drug and (71.3%) advised their patients to
read drug leaflet. Whereas 42.2% of pharmacists thought that it is important to notify the
dentist that the patient is taking Alendronate
drug.
Pharmacists Knowledge about alendronate interactions
In the section of food - Alendronate interactions: As can be seen in Table (2),
81.3% (n=187) of the respondents believed
that Alendronate could be taken with tap water, when 37.8% (n=87) reported that it could
be administered with mineral water. On the

other hand, 13.0% (n=30) responded that
Alendronate can be administered with coffee,
whereas, 13.5% (n=31) answered yes to the
question whether Alendronate can be administered with tea or not. Among all participants, a small number believed that it could
be taken with milk 25.2% (n=58). Furthermore, 35.2% (n=81) and 20.9% (n=48) believed that Alendronate could be taken with
fruit juices and dairy products, respectively.
Regarding pharmacists’ knowledge
about Alendronate drug-drug interactions
(Table 2). When the respondents were asked
about the specific Alendronate -drug interactions (59.6%) reported that Alendronate
could be taken concomitantly with calcium
supplements, (73%) with vitamin D without
affecting Alendronate absorption and
(34.3%) reported that it can be taken concomitantly with antacids. While, (30%) reported that Alendronate can be administered
with cortisone, and (58.7%) believed that it
can be taken with NSAIDS. Whereas,
(56.5%) reported that it can be taken with
Antibiotic.

Table (2): About Alendronate food-drug interactions.

Is it possible to administer it with the following
Food or beverages
Yes
No
Tap water
187 (81.3%)
37 (16.1%)
Mineral water
87 (37.8%)
123 (53.5%)
Milk

58 (25.2%)

146 (63.5%)

Coffee
Tea

30 (13.0%)
28 (12.2%)

Dairy products
Leafy vegetables
Fruit juices
Medications
Ca supplements
Vitamin D
Antacids
Cortisone

48 (20.9%)
83 (36.1%)
81 (35.2%)

168 (73.0%)
171
(74.3%)
150 (65.2%)
91 (39.6%)
97 (42.2%)

NSAIDS
Antibiotic

137 (59.6%)
168 (73%)
79 (34.3%)
69
(30%)
135 (58.7%)
130 (56.5%)

I don’t know
6 (2.6%)
20
(8.7%)
26
(11.3%)
32 (13.9%)
31 (13.5%)
32 (13.9%)
56 (24.3%)
52 (22.6%)

88 (38.3%)
54 (23.5%)
129 (56.1%)
131 (57%)

5 (2.2%)
8(3.5%)
22 (9.6%)
30 (13%)

72 (31.3%)
57 (24.8%)

23 (10%)
43 (18.7%)
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Pharmacists’ knowledge about Alendronate side effects

tic ulcer 51.3% (n=118) indigestion problems
58.7% (n=135), and difficulty swallowing
56.1% (n=129). Others reported side effects
were bleeding, periorbital and joint and muscle pains.

As we proceeded to the side effects section, the prevalence of side effects among
patients on alendronate therapy was reported
to be (Table 3): gastritis 86.5% (n=199), pepTable (3): The prevalence of side effects experienced by patients on Alendronate.
Side effects
Gastritis
Peptic ulcer
Bleeding
Indigestion
Difficulty in swallowing
Periorbital pain
Joint pain and muscle pain

Yes
199 (86.5%)
118 (51.3%)
59 (25.7%)
135 (58.7%)
129 (56.1%)
91 (39.6%)
106 (46.1%)

Relationship
between
the
sociodemographic properties of the pharmacists and the Knowledge scores
Table (4) shows the association between
the socio-demographic characteristics of the
pharmacists and the various knowledge
scores. The median knowledge score for
Alendronate use was intermediate 6 (1-9).
The median knowledge score use for Alen-

No
I don’t know
13 (5.7%)
18 (7.8%)
47 (20.4%)
65 (28.3%)
84 (36.5%)
87 (37.8%)
54 (23.5%)
41 (17.8%)
47 (20.4%)
54 (23.5%)
65 (28.3%)
74 (32.2%)
67 (29.1%)
57 (24.8%)
dronate interactions was10.5 (2-14), which
indicate good knowledge. Whereas, the median Alendronate side affects knowledge
score was 4 (0-8). Knowledge scores for females were higher than for males. Pharmacists who had experience years more than 40
years had higher knowledge score values
compared with less experienced pharmacists.

Table (4): The relationship between socio-demographic characteristics of the pharmacists and the
various knowledge scores.
Variable
Gender
Male
Female
Work locality
Urban
Rural
Camp
Educational level
Bachelor pharmacy
Doctor of pharmacy
Post graduated
Employment status
Pharmacy owner
Employee of pharmacy
Expert years
0-9
10-19
20-29
30-39
More than 40

Knowledge Score for
proper use
Inter quartiles
PMedian
value
6 (5-7)
6 (5-7)
6 (5-7)
6(5-7)
7(4.5-8)
6 (5-7)
6 (5-7)
6 (5-7)
6 (5-7)
6(5-7)
6 (5-7)
6 (5-7)
5 (4-7)
6 (5-7)
6 (5.5-7)

0.027

0.536

0.992

0.904

0.000

Knowledge Score for
interactions
Inter quartiles
PMedian
value
9(6-11)
10(8-12)
10(7-12)
10(8-12)
8(5-10)
10(7-11)
10(9-13)
10(9-14)
10(6-12)
10(8-11)
10(8-12)
9.5 (7-11)
9.5 (6-10)
11 (7.5-12.5)
6(4-8.5)

0.072

0.533

0.111

0.729

0.000

Knowledge Score for
Side effects
Inter quartiles
PMedian
value
4(2-6)
4(3-6)
4(3-6)
4(2-6)
4(2.5-5)
4(2-6)
5(4-6)
5(4-5)
4(2-6)
4(3-6)
4(3-6)
4(2-6)
3(1-5)
4(2.5-6)
5(4-5.5)

0.521

0.803

0.248

0.793

0.000
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DISCUSSION
Osteoporosis is a bone degenerative disease characterized by high risk of fractures.
Patient’s adherence to osteoporosis medications is suboptimal, which is considered a
problem that increases their potential to fractures. The experienced side effects and the
improper way of using oral bisphosphonate
medications by patients are strongly associated with bisphosphonate non-adherence.
Community pharmacies are the most accessible health care facilities to the patients.
Knowledge of pharmacists on the proper dosing information could greatly influence their
patient compliance to their therapy. The
pharmacist position is to deliver counseling
on the proper dosing instructions and the interactions of the medication to improve patient's awareness about the disease and adherence. The present study is the first study
of its kind in Palestine, which tried to assess
the knowledge of community pharmacists to
the proper dosing instructions and food-drug
interactions of Alendronate.
In this study we analyzed pharmacists'
knowledge in terms of Alendronate dosing
instructions, interactions and side effects,
which are described in this study as a
knowledge score. Furthermore, we tried to
find associations between pharmacist's sociodemographic characteristics, and their
knowledge of Alendronate therapy.
It was clear that Palestinian pharmacists
in general have an intermediate knowledge
towards the general dosing principles of
Alendronate (6/9). They have a good level of
knowledge regarding the food and drug interactions of Alendronate (10.5/14). However,
the pharmacists were least knowledgeable
about adverse effects experienced by the patients (4/8). More than half of them have inadequate knowledge to the instructions regarding concomitants drinks, food and medications. The Pharmacists were less aware of
the types of beverages that should not be administered with Alendronate.

Community pharmacists exhibit variable
knowledge of Alendronate dosing, adverse
effects, and interactions. These results are
similar to a previous study in Canada that
assessed pharmacist's knowledge of Alendronate dosing instructions and concluded that
there is a wide range of knowledge of
bisphosphonate dosing and delivery of pharmaceutical care amongst community pharmacists surveyed (20).
Moreover, higher scores were seen for
pharmacists who have longer years of experience (p value lees than 0.05). Older pharmacists might have more concern about medication use and interactions than younger pharmacists. However, these findings showed no
association between the different knowledge
scores and demographic factors such as age,
work place, work status and Education Level
(p value> 0.05). Intuitively, it may be expected that pharmacist with higher educational level should have better knowledge
about the Alendronate therapy.
However, there were no significant association between the higher level of education
and knowledge score. “Higher level of education does not mean better knowledge”.
Pharmacy owners had lower knowledge
score values than those who were employed
in the pharmacies. Pharmacists working in
camps had better knowledge score of proper
use than those in urban and rural areas. Urban pharmacists had a good side effects
knowledge score, whereas pharmacists in
rural had a good food-drug interactions
knowledge score.
Pharmacists have a significant role in
improving medication adherence among patients. A previous study in Malaysia indicated that pharmacists have a role in improving
medication adherence to Alendronate. Pharmacists have the responsibility of providing
the patient with information about the drug,
its potential side effects, the proper dosing
instructions, when to take the medication in
relation with food as well as types of beverages and medications to be avoided.
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The quality of pharmacists-patient relationship is one of the most important factors
to improve patients’ adherence (18, 19). Poor
pharmacists’ communication concerning the
benefits, instructions for use, and side effects
of medications can contribute to patients’
non-adherence. Pharmacists should assess
patient's understanding of their illness and
treatment, clearly communicate the benefits
of the treatment and identify and discuss any
barriers or obstacles to adherence, and formulate strategies for overcoming them with
the patient.
Moreover, they should be aware that the
crowded environment usually found in Palestinian community pharmacies may negatively
effect patients understanding of instructions
and medications adherence. Furthermore, it is
necessary for pharmacists to improve patients
understanding of Alendronate’s leaflet contents.
Avoidance of drug interactions does not
necessarily mean avoiding drugs or foods. In
the case of Alendronate and dairy products
and calcium supplement, these should simply
be taken at different times; rather than eliminating one or the other from the diet. In addition, it is imperative for healthcare providers
to keep up-to date on potential drug-food interactions of medications, in order to counsel
properly to their patients.
This study emphasizes the importance of
pharmacist’s role in educating the patients
about their drug therapy, and the benefits of
compliance with dosing instructions, which
in turn would help in improving future medical care in Palestine.
Efforts should be made to improve the
pharmacists' knowledge about the proper use
of Alendronate and food-drugs interactions
as well as to identify the barriers that may
interfere with the pharmacists’ proper
knowledge of instructions and implementing
the strategies to overcome them.
The ministry of health should implement
educational programs to educate health care
providers about Alendronate therapy. Education programs are required as presentations,

conferences’, workshops, study groups, home
study courses, reading journals, accessing
references’ materials and online distance educating courses about Alendronate proper
use, food-drug interactions and adverse effects.
CONCLUSIONS
In conclusion, the community pharmacists' knowledge towards the specific dosing
instructions of Alendronate medication and
its –food and-drug interactions was intermediate knowledge. There is a need to have
training programs to improve the knowledge
of pharmacists on the proper dosing instructions and interactions of Alendronate, which
could greatly influence the impact on patient
compliance to their medication.
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